Edgewise Therapeutics' stock rose significantly after positive midstage trial results for its Becker Muscular Dystrophy program. The lead molecule, sevasemten, showed promising results, and the company is aiming for regulatory approval. With a market cap of $2.67 billion and a cash runway of 8-9 quarters, Edgewise is well-positioned for ongoing and future trials.